Morphological changes that may arise through a treatment course are probably one of the most significant sources of range uncertainty in proton therapy. Non-invasive in-vivo treatment monitoring is useful to increase treatment quality. The INSIDE in-beam Positron Emission Tomography (PET) scanner performs in-vivo range monitoring in proton and carbon therapy treatments at the National Center of Oncological Hadrontherapy (CNAO). It is currently in a clinical trial (ID: NCT03662373) and has acquired in-beam PET data during the treatment of various patients. In this work we analyze the in-beam PET (IB-PET) data of eight patients treated with proton therapy at CNAO. The goal of the analysis is twofold. First, we assess the level of experimental fluctuations in inter-fractional range differences (sensitivity) of the INSIDE PET system by studying patients without morphological changes. Second, we use the obtained results to see whether we can observe anomalously large range variations in patients where morphological changes have occurred. The sensitivity of the INSIDE IB-PET scanner was quantified as the standard deviation of the range difference distributions observed for six patients that did not show morphological changes. Inter-fractional range variations with respect to a reference distribution were estimated using the Most-Likely-Shift (MLS) method. To establish the efficacy of this method, we made a comparison with the Beam's Eye View (BEV) method. For patients showing no morphological changes in the control CT the average range variation standard deviation was found to be 2.5 mm with the MLS method and 2.3 mm with the BEV method. On the other hand, for patients where some small anatomical changes occurred, we found larger standard deviation values. In these patients we evaluated where anomalous range differences were found and compared them with the CT. We found that the identified regions were mostly in agreement with the morphological changes seen in the CT scan.

In-vivo range verification analysis with in-beam PET data for patients treated with proton therapy at CNAO / Moglioni, Martina; Kraan, Aafke Christine; Baroni, Guido; Battistoni, Giuseppe; Belcari, Nicola; Berti, Andrea; Carra, Pietro; Cerello, Piergiorgio; Ciocca, Mario; De Gregorio, Angelica; De Simoni, Micol; Del Sarto, Damiano; Donetti, Marco; Dong, Yunsheng; Embriaco, Alessia; Fantacci, Maria Evelina; Ferrero, Veronica; Fiorina, Elisa; Fischetti, Marta; Franciosini, Gaia; Giraudo, Giuseppe; Laruina, Francesco; Maestri, Davide; Magi, Marco; Magro, Giuseppe; Malekzadeh, Etesam; Marafini, Michela; Mattei, Ilaria; Mazzoni, Enrico; Mereu, Paolo; Mirandola, Alfredo; Morrocchi, Matteo; Muraro, Silvia; Orlandi, Ester; Patera, Vincenzo; Pennazio, Francesco; Pullia, Marco; Retico, Alessandra; Rivetti, Angelo; Da Rocha Rolo, Manuel Dionisio; Rosso, Valeria; Sarti, Alessio; Schiavi, Angelo; Sciubba, Adalberto; Sportelli, Giancarlo; Tampellini, Sara; Toppi, Marco; Traini, Giacomo; Trigilio, Antonio; Valle, Serena Marta; Valvo, Francesca; Vischioni, Barbara; Vitolo, Viviana; Wheadon, Richard; Bisogni, Maria Giuseppina. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 12:(2022), p. 929949. [10.3389/fonc.2022.929949]

In-vivo range verification analysis with in-beam PET data for patients treated with proton therapy at CNAO

Berti, Andrea;Ciocca, Mario;De Gregorio, Angelica;De Simoni, Micol;Fischetti, Marta;Franciosini, Gaia;Magi, Marco;Magro, Giuseppe;Patera, Vincenzo;Retico, Alessandra;Sarti, Alessio;Schiavi, Angelo;Sciubba, Adalberto;Toppi, Marco;Trigilio, Antonio;
2022

Abstract

Morphological changes that may arise through a treatment course are probably one of the most significant sources of range uncertainty in proton therapy. Non-invasive in-vivo treatment monitoring is useful to increase treatment quality. The INSIDE in-beam Positron Emission Tomography (PET) scanner performs in-vivo range monitoring in proton and carbon therapy treatments at the National Center of Oncological Hadrontherapy (CNAO). It is currently in a clinical trial (ID: NCT03662373) and has acquired in-beam PET data during the treatment of various patients. In this work we analyze the in-beam PET (IB-PET) data of eight patients treated with proton therapy at CNAO. The goal of the analysis is twofold. First, we assess the level of experimental fluctuations in inter-fractional range differences (sensitivity) of the INSIDE PET system by studying patients without morphological changes. Second, we use the obtained results to see whether we can observe anomalously large range variations in patients where morphological changes have occurred. The sensitivity of the INSIDE IB-PET scanner was quantified as the standard deviation of the range difference distributions observed for six patients that did not show morphological changes. Inter-fractional range variations with respect to a reference distribution were estimated using the Most-Likely-Shift (MLS) method. To establish the efficacy of this method, we made a comparison with the Beam's Eye View (BEV) method. For patients showing no morphological changes in the control CT the average range variation standard deviation was found to be 2.5 mm with the MLS method and 2.3 mm with the BEV method. On the other hand, for patients where some small anatomical changes occurred, we found larger standard deviation values. In these patients we evaluated where anomalous range differences were found and compared them with the CT. We found that the identified regions were mostly in agreement with the morphological changes seen in the CT scan.
2022
clinical trial; in-beam PET imaging; in-vivo treatment verification; inter-fractional range differences; morphological changes; proton therapy
01 Pubblicazione su rivista::01a Articolo in rivista
In-vivo range verification analysis with in-beam PET data for patients treated with proton therapy at CNAO / Moglioni, Martina; Kraan, Aafke Christine; Baroni, Guido; Battistoni, Giuseppe; Belcari, Nicola; Berti, Andrea; Carra, Pietro; Cerello, Piergiorgio; Ciocca, Mario; De Gregorio, Angelica; De Simoni, Micol; Del Sarto, Damiano; Donetti, Marco; Dong, Yunsheng; Embriaco, Alessia; Fantacci, Maria Evelina; Ferrero, Veronica; Fiorina, Elisa; Fischetti, Marta; Franciosini, Gaia; Giraudo, Giuseppe; Laruina, Francesco; Maestri, Davide; Magi, Marco; Magro, Giuseppe; Malekzadeh, Etesam; Marafini, Michela; Mattei, Ilaria; Mazzoni, Enrico; Mereu, Paolo; Mirandola, Alfredo; Morrocchi, Matteo; Muraro, Silvia; Orlandi, Ester; Patera, Vincenzo; Pennazio, Francesco; Pullia, Marco; Retico, Alessandra; Rivetti, Angelo; Da Rocha Rolo, Manuel Dionisio; Rosso, Valeria; Sarti, Alessio; Schiavi, Angelo; Sciubba, Adalberto; Sportelli, Giancarlo; Tampellini, Sara; Toppi, Marco; Traini, Giacomo; Trigilio, Antonio; Valle, Serena Marta; Valvo, Francesca; Vischioni, Barbara; Vitolo, Viviana; Wheadon, Richard; Bisogni, Maria Giuseppina. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 12:(2022), p. 929949. [10.3389/fonc.2022.929949]
File allegati a questo prodotto
File Dimensione Formato  
Moglioni_In-vivo range verification_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 7.07 MB
Formato Adobe PDF
7.07 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1666538
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact